Abstract Reversible posterior leukoencephalopathy syndrome (RPLS) is a serious neurologic disease characterized by visual disturbance, seizures, headache, and altered mental status associated with white matter changes, particularly in the occipital lobes. RPLS has been attributed to chemotherapy, including modified FOLFOX6 regimens consisting of 5-fluorouracil, oxaliplatin, and leucovorin. Although the mechanism of development of RPLS remains unclear, impaired cerebral blood flow autoregulation and endothelial dysfunction seem to be involved. In particular, endothelial dysfunction has been implicated in the pathophysiology of RPLS associated with platinum agents. Platinum-based chemotherapy is thought to have a direct toxic effect on the vascular endothelium, leading to capillary leakage, disruption of the blood-brain barrier, and axonal swelling, triggering vasogenic edema. Much progress has been made in chemotherapy for colorectal cancer, and the increasing use of molecular-targeted agents is expected to further improve the outcome of therapy. RPLS has recently been associated with such molecular-targeted therapy, particularly in patients concurrently receiving platinum agents. This finding is consistent with previous reports suggesting that RPLS occurs more often in patients receiving platinum-based therapy than in those receiving molecular-targeted agents. Because platinum agents are the most widely used in cancer chemotherapy, clinicians should strongly suspect RPLS in patients receiving treatment with this class of drug.
Introduction
Reversible posterior leukoencephalopathy syndrome (RPLS) is a serious neurological syndrome characterized by visual disturbance, seizures, headache, and altered mental status associated with white matter changes, particularly in the occipital lobes. Although the mechanism underlying RPLS has not been fully elucidated, RPLS reportedly develops during chemotherapy. Chemotherapy for colorectal cancer has progressed markedly, and such cancer now has a relatively good prognosis when used in combination with FOLFOX or FOLFIRI, among other regimens. Additionally, with the increasing use of molecular-targeted agents, for example bevacizumab, cetuximab, and panitumumab, further improved therapeutic outcomes are expected. Current chemotherapy methods are reported to be associated with a variety of adverse events, but reports documenting association of RPLS with chemotherapy for colorectal cancer are relatively rare. We report a case of RPLS caused by mFOLFOX6 chemotherapy for metastatic sigmoid colon cancer.
Case report
The patient was a 43-year-old woman with sigmoid colon cancer and multiple liver metastases. There was no history of epilepsy, renal failure, or hypertension. She was administered mFOLFOX6 with leucovorin 200 mg/m 2 as a 2-h infusion and oxaliplatin 85 mg/m 2 as a 2-h infusion, followed by bolus 5-fluorouracil 400 mg/m 2 and a 46-h infusion of 5-fluorouracil 2400 mg/m 2 , repeated every 2 weeks. Early in the morning of day 11, nausea with headache, disturbed consciousness, and visual disturbance developed, and the patient was subsequently transported to the hospital by ambulance. On admission to the emergency room (ER), her vital signs were relatively normal, except for a blood pressure of 177/94 mmHg. Severe nausea suddenly occurred, and generalized tonic-chronic seizures subsequently developed. Seizures subsided after treatment with diazepam. On the evening of day 11, another episode of generalized tonic-chronic seizures occurred, and the patient received diazepam and phenytoin but did not respond. Status epilepticus developed, and tracheal intubation was performed for airway protection. An intravenous infusion of propofol was administered to control the seizures. Cranial magnetic resonance imaging (MRI) revealed intense signals in both occipital lobes; these were centered at the boundary between the gray matter and white matter on fluid-attenuated inversion recovery (FLAIR) images (Fig. 1a) . There was no evidence of metastases, hemorrhage, or infarction in the brain. Hematologic, serum chemical, and cerebrospinal fluid examinations revealed no remarkable changes. Hematologic and blood biochemical tests revealed no inflammation, and the results were negative for a variety of viral markers and antinuclear antibodies. After intubation, her condition stabilized with no seizure recurrence. Although hypertension was present on admission to the ER, blood pressure gradually decreased to the normal range without antihypertensive treatment. On day 18 she was extubated. No neurologic sequelae were observed. Encephaloencephalography did not reveal any particular abnormality. Cranial MRI on day 40 showed that the intense signals in both occipital lobes had nearly disappeared (Fig. 1b) . This clinical course and the laboratory/ imaging findings did not seem to be consistent with cerebral infarction, demyelinating disease, angiitis, or encephalitis. Because the patient's condition was characterized by a reversible central nervous system disorder, the possibility of RPLS was considered. Although symptoms of RPLS improved, her colon cancer worsened. The patient died on day 113 without receiving further chemotherapy.
Discussion
In 1996, Hinchey et al. [1] described 15 patients with a reversible syndrome characterized by headache, disturbed consciousness, seizures, and vision loss associated with predominantly posterior lesions on imaging studies. It is not entirely known why RPLS favors posterior circulation, but it may be because of the relative lack of sympathetic innervation at the level of the arterioles supplied by the vertebrobasilar system compared with that in the anterior circulation [2] . Because the symptoms of these patients resolved markedly or disappeared, this entity was called ''RPLS''. To date, diagnostic criteria for RPLS remain to be established. The diagnosis is therefore based on the clinical course, imaging findings and the exclusion of brain tumors, cerebral infarction, toxic or metabolic encephalitis, and vasculitis. Although the mechanism of RPLS remains to be fully elucidated, several conditions are apparently of crucial importance in its pathogenesis. Hypertensive Fig. 1 According to this review of the literature, development of RPLS is more frequent in women, i.e., 16 out of 20 cases reported, but the relationship of the syndrome with gender remains unclear because there have been reports of cases of overt RPLS associated with non-platinum-containing anticancer drugs or other regimens. RPLS associated with eclampsia has, nevertheless, been reported; the accumulation of fluid often observed during pregnancy may have increased the tendency for brain edema to develop [1] . Time of onset of the syndrome is not evaluable because of its variability with therapy regimen, but it ranged from after the first cycle of chemotherapy to after the 13th cycle. In cases of colorectal cancer, RPLS developed after the first cycle (days 11-12 of Cycle 1) in all patients receiving FOLFOX therapy. However, development of PRLS was in the 4th cycle or thereafter (up to Cycle 10) in patients receiving FOLFOX ? Bmab therapy. Recent reports have ascribed this syndrome to molecular-targeted agents such as bevacizumab, sorafenib, and sunitinib, but all 7 patients with RPLS who received molecular-targeted therapy were concurrently administered platinum agents. This finding is consistent with those of previous studies reporting that RPLS is more common in patients receiving platinumbased therapy than in those receiving molecular-targeted agents [4] . All drugs can potentially cause RPLS in individual patients. Clinicians should be aware that not only molecular-targeted therapy but also platinum agents can cause RPLS. Cisplatin reportedly causes vascular disruption, resulting in cerebral vascular accidents, myocardial FOLFOX 5-fluorouracil, leucovorin, oxaliplatin, XELOX capecitabine, leucovorin, oxaliplatin, GEMOX gemcitabine, oxaliplatin, GC gemcitabine, cisplatin, PVB cisplatin, bleomycin, vinblastine, BEP cisplatin, etoposide, bleomycin, NA not available a Nearly normal throughout the entire clinical course infarction, and Raynaud's syndrome [22] . Platinum may have direct toxic effects on vascular endothelial cells, similarly to agents that cause vascular disruption [23] , which potentially leads to abnormal fluctuations in blood pressure and breakdown of the BBB. Although the possibility that RPLS might have developed as a result of the vascular endothelial toxicity of 5-fluorouracil cannot be completely ruled out, the cerebral toxicity of 5-fluorouracil is well-described as a multifocal inflammatory leukoencephalopathy. Multifocal inflammatory leukoencephalopathy typically develops 6 weeks to 5 months after the initiation of chemotherapy, and is a clinically and radiographically distinct syndrome from RPLS, making it unlikely that 5-fluorouracil was the cause of the RPLS in this patient [24, 25] . Therefore, we hypothesize that platinuminduced vasculoendothelial damage in our patient led to RPLS development. Given the recent increases in the prevalence of colorectal cancer, clinicians should recognize RPLS as a potential complication related to treatment with platinum agents and molecular-targeted therapy.
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